Markets

Why Intersect ENT Is Down Big Today

What happened

Shares of Intersect ENT (NASDAQ: XENT), a medical device company focused on products that treat ear, nose, and throat problems, are down 17% as of 2:10 p.m. EDT on Friday. The huge drop is attributable to disappointing quarterly results.

So what

Here are Intersect ENT's headline numbers from the quarter:

  • Revenue rose 1% to $26.7 million. That was slightly behind Wall Street's estimate.
  • Gross margin improved by 200 basis points to 81%.
  • Operating expenses jumped 33% to $33.7 million.
  • Net loss more than doubled to $11.4 million, or $0.36 per share. That was worse than the $0.34-per-share loss analysts were expecting.
  • Cash balance at quarter-end was $93.5 million.

The worse-than-expected quarterly results were bad enough, but management poured salt on the wound by cutting guidance, too:

  • Full-year revenue is now expected to be about flat, at $108.5 million. That's down from Intersect's prior range of $113 million to $117 million.
  • 2019 operating expenses are still expected to land between $135 million and $137 million.
Businessman at laptop giving the thumbs-down sign

Image source: Getty Images.

Given the poor results and guidance cut, it's no surprise to see shares getting whacked again.

Now what

Intersect ENT recently hired Tom West as its new CEO. West has been in the medical device industry for a long time and has held executive roles at Hologic and at Johnson & Johnson, so he seems to be a good fit to turn this business around.

If West can return Intersect ENT to growth, then shares could be viewed as a bargain today. However, that's easier said than done. That's why my plan remains to root for Intersect's success from the safety of the sidelines, and to be willing to jump in only after we see clear signs that the recovery is taking hold.

10 stocks we like better than Intersect ENT
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Intersect ENT wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 1, 2019

 

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

XENT

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More